Form 4: Pulmonx Director Sells Shares Under 10b5-1 Plan

Pulmonx Director Daniel P. Florin sold 23,321 shares of common stock for a weighted average price of $1.99 per share, pursuant to a Rule 10b5-1 trading plan.

Summary

• Daniel P. Florin, a Director of Pulmonx Corp (LUNG), reported the sale of 23,321 shares of common stock.
• The transaction occurred on December 8, 2025.
• The shares were sold at a weighted average price of $1.99 per share, with individual transaction prices ranging from $1.97 to $2.03.
• The sale was executed under a Rule 10b5-1 trading plan adopted by Mr. Florin on June 13, 2025.
• Following this transaction, Mr. Florin beneficially owns 93,910 shares of Pulmonx common stock.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider sale under a 10b5-1 plan, which is a routine event and typically does not indicate new positive or negative information about the company's operational performance or future prospects. The future dates for the transaction and filing are unusual but are reported as per the document.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan is generally not considered a strong signal of management's view on the company's future, as it is pre-scheduled for personal financial planning purposes. The impact on shareholder sentiment is likely minimal.

Key Dates

Recommendation

The filing details a pre-planned sale of shares by a director under a Rule 10b5-1 trading plan. Such transactions are typically for personal financial management and are not usually indicative of new material information about the company's performance or outlook. Therefore, this specific filing does not provide a basis for changing an investment recommendation, suggesting a 'hold' position remains appropriate based solely on this information.

Keywords

Pulmonx, LUNG, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan